MSD Announces Participation in the 4th China International Import Expo with Innovative Portfolio and Pipeline Highlights

ShanghaiSeptember 15, 2021 /PRNewswire/ -- MSDChina(MSD is the business name of Merck & Co., Inc., Kenilworth, New Jersey, USA)Todayannounced participationParticipate in the 4th China International Import Expo (hereinafter referred to as "CIIE") held at the National Exhibition and Convention Center (Shanghai) from November 5 to 10, 2021. As a global leading biopharmaceutical company, MSD, which has participated in the expo for three consecutive years, will comprehensively showcase at this premier event its extensive product portfolio and R&D pipeline, innovative healthcare solutions, and its long-term commitment to deepening its presence in the Chinese market and benefiting Chinese patients.

MSD’s booth at this year’s CIIE is located at Booth A01-003 in Hall 7.2. Spanning over 1,000 square meters, the open exhibition space will feature dedicated zones showcasing milestones of MSD’s growth in China, the latest advancements in global clinical research and development, a comprehensive portfolio of human health and animal health products, digital innovation solutions, and the company’s long-term commitment to the Chinese market and patients. The exhibit will demonstrate to visiting government officials, corporate representatives, partners, media, and the public MSD’s contributions over the past 130 years to advancing human health, as well as its unremitting efforts to improve the accessibility of medicines, vaccines, and health knowledge.

Schematic Diagram of MSD Booth at the 4th China International Import Expo

Anna Tian, President of MSD China, stated: “This year marks the 130th anniversary of MSD globally, as well as my first year in this role. I am delighted to join everyone at the 4th China International Import Expo. As a long-term partner and participant in the CIIE, MSD will work closely with our partners across China to strengthen communication and sharing, and jointly address global public health threats. China has always been one of MSD’s most important markets. We will steadfastly uphold our mission of ‘Enriching Life — For Patients, For Health’ by continuously introducing more life-saving innovative medicines and advanced vaccines to China, ensuring they reach Chinese patients and the public faster and more effectively, and supporting China in accelerating the realization of the ‘Healthy China 2030’ goals.”

2021 marks the beginning of a new decade for the "Healthy China 2030" strategy and also serves as the inaugural year of China's "14th Five-Year Plan". The Chinese government places safeguarding public health at a strategic priority for development, emphasizing a prevention-first health policy and focusing on major diseases and key issues that affect people's health. MSD will consistently uphold the value that "medicine is for people, not for profit," continuously exploring, developing, and providing high-quality innovative medicines, vaccines, and health solutions to improve the quality of life for patients in China, enhance the health of the Chinese public, and contribute to advancing the Healthy China initiative.